Current cancer immunotherapies that use dendritic cells are limited by complex manufacturing, high variability, and the need for patient-specific cell preparation, which restricts scalability and rapid deployment across multiple tumor types.

PDC*line Pharma develops off‑the‑shelf therapeutic cancer vaccines using a proprietary allogeneic plasmacytoid dendritic cell line (PDC*line). The platform enables rapid loading of tumor‑associated peptide antigens to generate potent cytotoxic CD8⁺ T‑cell responses. Because the cell line is manufactured at scale, vaccines can be produced in large, consistent batches and administered without individualized cell processing. Clinical programs currently evaluate PDC*lung01 in lung cancer (combined with pembrolizumab) and PDC*neo in colorectal cancer, with earlier phase data showing promising efficacy in melanoma and lung cancer. The approach aims to provide a versatile, scalable immunotherapy that can be quickly adapted to new antigens and cancer indications.

Proprietary allogeneic plasmacytoid dendritic cell line offering higher potency than conventional dendritic cells for CD8⁺ T‑cell activation

Off‑the‑shelf manufacturing enables large‑scale, consistent production and reduces logistical complexity

Flexible antigen loading allows rapid generation of vaccines targeting diverse tumor antigens, including neoantigens

Clinical-stage programs in melanoma, lung, and colorectal cancers with combination strategies (e.g., pembrolizumab)

Robust preclinical and early clinical data demonstrating strong cytotoxic immune responses and favorable safety profile

Primary customers are oncology pharmaceutical companies and clinical researchers seeking scalable, antigen‑specific cancer vaccine platforms for combination immunotherapy trials.